Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Welcome and Introduction to Vi3C

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Apr
23
Today In Oncology
Long-Term Immunotherapy for Alveolar Soft Part Sarcoma
AMA Data Show Nearly 50 Percent of Surveyed Oncologists Reported Burnout in 2025
Unique Phase I NSCLC Trial Sites Decreasing in United States
Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo